Above and Beyond - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Above and Beyond
Industry efforts toward global healthcare surpass average expectations.


Pharmaceutical Technology
Volume 34, Issue 9, pp. 14


Angie Drakulich
When our team set out to cover how pharmaceutical companies are addressing issues of global healthcare, including providing access to medicines to those who need it most, we were amazed at the high level of corporate philanthropy. A simple flip through the Developing World Health Partnerships Directory highlights this fact. The International Federation of Pharmaceutical Manufacturers (IFPMA) publishes the directory each year, and the 2010 edition showcases more than 200 programs carried out by pharma, nongovernmental and nonprofit organizations, governments, charities, and global partnerships. The groups are working to develop and deliver treatments that target diseases prevalent within developing nations. Research and development (R&D) efforts, for example, focus on HIV/AIDS, malaria, tuberculosis, and chronic and tropical diseases.

Much of the work being done also includes educational/awareness programs, capacity building, transportation, infrastructure, and technical support. Most all of the programs correlate directly with the United Nations Millennium Development Goals (MDGs) as well. The MDGs, many of which target health and healthcare, aim to reduce extreme poverty worldwide.

The directory can be searched online at http://www.ifpma.org/healthpartnerships/. Also of interest is the 2010 Access to Medicines Index, a publication put out by the international Access to Medicine Foundation. This index ( http://www.accesstomedicineindex.org/) analyzes and ranks access-to-medicines efforts of the world's largest pharmaceutical companies. Check out PharmTech's ongoing coverage of the pharmaceutical industry's efforts to improve global healthcare beginning next month.

Angie Drakulich is the managing editor of Pharmaceutical Technology.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here